Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

18 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-11-30

Study Completion Date

2017-09-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to document safety and efficacy of renal sympathetic denervation treatment in subjects with uncontrolled hypertension by using Iberis renal denervation system.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Renal Denervation by Iberis MultiElectrode Renal Denervation System in Patients With Primary Hypertension

NCT02901704

Primary Hypertension

UNKNOWN PHASE3

Renal Artery DenervatIon Using Radial accesS in Uncontrolled HyperTensioN

NCT05234788

Hypertension

RECRUITING NA

Study of Catheter Based Renal Denervation Therapy in Hypertension

NCT01522430

Resistant Hypertension Renal Denervation Ambulatory Blood Pressure +1 more

UNKNOWN PHASE3

A Study to Evaluate Safety and Efficacy of the Redy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension

NCT02690909

Hypertension Resistant to Conventional Therapy

UNKNOWN NA

Renal Denervation in Treatment Resistant Hypertension

NCT01687725

Hypertension

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a prospective, multi-center, single-arm, non-interventional and open-label registry to collect descriptive data from patients who receive renal sympathetic denervation treatment in accordance with routine hospital practice using Iberis system.

This registry will collect data prospectively from patients that receive renal sympathetic denervation treatment with use of Iberis renal denervation system and treatment will be applied according to the routine hospital practice. No additional tests are required specific to this registry. The registry will serve as a tool to collect clinical data in order to expand the knowledge base of safety, efficacy and functionality of the Iberis system in patients with resistant hypertension.

A minimum of 30 patients will be enrolled in Europe

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Resistant Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Renal Denervation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years or minimum age as required by local regulations.
* Patient has been thoroughly informed about this registry and signed Informed Consent Form.
* Patient with true resistant hypertension defined as:

* Office systolic BP higher than 160 or 150mmHg in case of type 2 diabetes
* Ambulatory BP with average BP\>130mmHg or mean daytime\>135mmHg in more than 70% of the measurements.
* Patients should be on stable hypertension therapy for at least 8 weeks before procedure, including spironolactone if they are supposed to be respondent as indicated by the specialized center/excellence unit on hypertension.

Exclusion Criteria

* Previous renal artery intervention (balloon angioplasty or stenting).
* Evidence of renal artery atherosclerosis (defined as a renal artery stenosis \>50%).
* Main renal arteries of less than 4mm diameter or less than 20mm in length.
* Presence of multiple main renal arteries in either kidney.
* Estimated glomerular filtration rate \<45ml/min per 1,73m2
* Recent myocardial infarction, unstable angina pectoris or cerebrovascular accident within the past 3-6 months.
* False resistant hypertension (pseudo resistance) by using 24h ambulatory BP monitoring (ABPM).
* Secondary arterial hypertension.
* Pregnancy.
* There is another pathological process with well-known life expectancy of less than 5 years.
* Patient unable to do correct FU.
* Unable to take correct ambulatory BP.
* Primary hyperaldosteronism.
* Known lack of adherence to medical treatment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No